Developer docs
API playgroundTry for free, no card

Search company profiles

Sebia

Full company profile

uuid0005uaa

Namestring
Sebia
Legal namestring
Sebia S.A.
Websiteurl
sebia.com
Company typeenum
Private
Founded yearint
1967
Descriptiontext

Sebia is a global In Vitro Diagnostic (IVD) company founded in 1967 and headquartered in Evry, France, specializing in clinical protein electrophoresis equipment and reagents. The company provides a comprehensive portfolio of instruments, tests, software, and services to clinical diagnostic laboratories across 120+ countries, with 20,000+ installed instruments and 1,300+ employees worldwide. Its core technology platforms include Capillary Electrophoresis (CAPILLARYS 3 family, MINICAP), Gel Electrophoresis (HYDRASYS 2), IFA automation (dIFine microscope with AI-powered pattern recognition), and random-access ELISA (Alegria 2 with 130+ tests). The proprietary PHORESIS software manages data analysis across electrophoresis instruments, while Sebia Academy, Sebia Lean Service, and Sebia Service provide education, optimization, and technical support.

The company's test menu addresses five primary clinical areas: oncology (Multiple Myeloma diagnosis via serum protein electrophoresis, immunofixation, immunotyping, and Free Light Chains with 96.8% concordance to IMWG criteria), metabolic disorders (HbA1c for diabetes, CDT for alcoholism), hemoglobinopathies (newborn and patient screening covering 500+ variants), autoimmune diseases (ANA, ANCA, vasculitis, connective tissue disease panels), and infectious diseases. Sebia holds regulatory clearances including FDA approvals for FLC Kappa & Lambda assays (2024) and CAPILLARYS 3 DBS (2024), plus IFCC standardization for CDT testing.

Sebia's business model combines hardware sales (instruments) with high-margin recurring revenue from proprietary test reagents and consumables tied to the installed instrument base, supplemented by service and education revenue. The company distributes through a global direct enterprise sales force targeting clinical laboratories, with integration partnerships with major lab automation vendors (Inpeco FlexLab, Siemens Healthineers Aptio, PerkinElmer). The company is privately held, with private equity firms CVC Funds, La Caisse, and Téthys Invest as existing investors; in late 2025, Warburg Pincus announced acquisition of a significant minority stake (EC-approved December 2025, closing expected Q1 2026). Sebia has pursued an active M&A strategy, acquiring Orgentec Diagnostika (2021) and ZEUS Scientific (2022) to expand autoimmune and infectious disease capabilities, and entered a strategic partnership with ABIONYX Pharma (2025) for sepsis diagnostics development.

Short descriptiontext

Sebia is a global In Vitro Diagnostic company specializing in clinical protein electrophoresis instruments, reagents, and autoimmune disease tests, serving clinical diagnostic laboratories across 120+ countries with 20,000+ installed instruments and a recurring reagent revenue model.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersLisses, France
HQ citystring
Lisses
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
in vitro diagnostics, capillary electrophoresis, protein electrophoresis, diagnostic reagents, clinical laboratory equipment
Industry2 codes
PRIMARYHLAHAAAB
Hematology & Coagulation Diagnostics
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAHAAAM
IVD Reagents, Assay Kits & Consumables (Non-instrument)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
NAICS code2 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • Laboratory Analytical Instruments3826
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
In Vitro Diagnostics (Clinical Laboratory Equipment and Reagents)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1IVD Instruments and Hardware
TypeHardware Sales
Description

Sale of electrophoresis instruments including CAPILLARYS family, MINICAP, HYDRASYS, dIFine, and Alegria 2 systems to clinical laboratories.

sebia.com
2Diagnostic Reagents and Tests
TypeSubscription Recurring
Description

Recurring revenue from proprietary test reagents, consumables, and assay kits for the installed instrument base covering protein electrophoresis, immunotyping, FLC, HbA1c, hemoglobin, CDT, autoimmune and infectious disease tests.

sebia.com
3Service and Support
TypeProfessional Services
Description

Sebia Service for technical and scientific support, Sebia Lean Service for laboratory performance optimization, and Sebia Academy for customer education.

sebia.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1Orgentec
Description

Brand under Sebia offering for autoimmune and infectious disease diagnostic tests, including ORG-prefixed products.

sebia.com
+4 more records
Core offering1 text field

Sebia manufactures and sells in vitro diagnostic instruments (capillary electrophoresis, gel electrophoresis, IFA automation, and random-access ELISA systems), proprietary test reagents and consumables, the PHORESIS data analysis software, and laboratory support services for clinical diagnostic laboratories worldwide. Its test portfolio spans multiple myeloma, diabetes, hemoglobinopathies, autoimmune, and infectious disease diagnostics, with 20,000+ instruments installed in 120+ countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Clinical performance of 96.8% concordance for FLC testing based on IMWG criteria
+2 more records
Product overview1 text field

Sebia is a global specialized In Vitro Diagnostic company providing a comprehensive portfolio of instruments, tests, software, and services for clinical diagnosis laboratories. The core technology platform includes Capillary Electrophoresis instruments (CAPILLARYS 3 family, MINICAP), Gel Electrophoresis (HYDRASYS 2), IFA automation (dIFine microscope and P30 processor), and random-access ELISA (Alegria 2). These instruments run tests across key clinical areas: Oncology (Multiple Myeloma diagnosis via serum protein electrophoresis, immunofixation, immunotyping, and Free Light Chains), Metabolic Disorders (HbA1c for diabetes, CDT for alcoholism), Hemoglobinopathies (newborn and patient screening), and Autoimmune/Infectious Diseases (ANA, ANCA, anti-CCP, anti-MCV, thyroid, celiac, vasculitis panels). The proprietary PHORESIS software manages data analysis across electrophoresis instruments, while Sebia Academy, Sebia Lean Service, and Sebia Service provide education and support. Acquired brands include Orgentec (autoimmune/infectious disease ELISAs) and Zeus Scientific. The MySebia portal provides customer self-service access.

Product and service20 records
1CAPILLARYS 3 TERA TLA
CategoryInstrument
Description

High-throughput capillary electrophoresis instrument with total lab automation connectivity to Inpeco FlexLab and Siemens Healthineers Aptio tracks, processing up to 87 protein electrophoresis results per hour. For high-volume clinical diagnostic laboratories.

2CAPILLARYS 3 TERA
CategoryInstrument
Description

Multiparametric capillary electrophoresis instrument combining precision, high-quality separation, and high throughput for protein electrophoresis, immunotyping, and HbA1c testing. For medium-to-high volume clinical laboratories.

3CAPILLARYS 3 OCTA
CategoryInstrument
Description

Capillary electrophoresis system for medium-to-high volume laboratories requiring multiple simultaneous electrophoretic separations.

4CAPILLARYS 3 DBS
CategoryInstrument
Description

FDA-cleared automated capillary electrophoresis instrument dedicated to newborn hemoglobin disorders screening using dried blood spots, with up to 70 samples/hour throughput and full traceability from sample punch to result. For newborn screening programs.

5MINICAP FLEX-PIERCING
CategoryInstrument
Description

Compact, fully automated capillary electrophoresis instrument for small-to-medium size laboratories offering seven available techniques including protein, immunotyping, HbA1c, hemoglobin, and CDT testing.

6dIFine automated microscope
CategoryInstrument
Description

Fully automated IFA microscope with AI-powered ANA pattern recognition using computer vision, processing up to 96 fields per run at 8 seconds per well, with integrated image atlas for ICAP-compliant pattern validation. For autoimmune disease testing laboratories.

7dIFine P30 processor
CategoryInstrument
Description

Walk-away benchtop instrument for automated IFA slide processing, handling up to 240 samples and 30 slides per run with full traceability from dilution to cover slipping. For autoimmune and immunology laboratories.

8HYDRASYS 2 SCAN FOCUSING
CategoryInstrument
Description

Semi-automated gel electrophoresis instrument for isoelectrofocusing and immunofixation, used with HYDRAGEL kits for CNS IgG oligoclonal band detection in multiple sclerosis diagnosis. For clinical laboratories performing neurological disease testing.

9Alegria 2
CategoryInstrument
Description

Fully automated random-access ELISA-based analyzer using Monotest technology for autoimmune and infectious disease diagnostics, offering a customizable panel of over 130 tests with continuous loading and on-board quality control. For clinical autoimmune and infectious disease laboratories.

10PHORESIS Software
CategorySoftware
Description

Proprietary data analysis and interpretation software for Sebia electrophoresis assays, facilitating efficient result management and analysis across all Sebia instruments. For clinical laboratories running Sebia instruments.

11Free Light Chains (FLC) Kappa & Lambda
CategoryDiagnostic Test
Description

FDA-cleared ELISA assay for quantification of kappa and lambda free light chains in serum, used as an aid in diagnosis and monitoring of Multiple Myeloma and AL amyloidosis with 96.8% concordance to IMWG criteria. For clinical laboratories and oncology departments.

12Carbohydrate Deficient Transferrin (CDT)
CategoryDiagnostic Test
Description

IFCC-standardized biomarker test for chronic alcohol abuse detection using capillary electrophoresis, with CDTIFCC percent value automatically calculated. For clinical and forensic laboratories.

13Hemoglobin Disorders Screening
CategoryDiagnostic Test
Description

Capillary electrophoresis-based hemoglobin variant screening enabling high-resolution separation of Hb S, C, D, and E variants with accurate quantification of Hb A2 and Hb F, covering over 500 hemoglobin variants. For newborn screening and hemoglobinopathy reference laboratories.

14CNS Local IgG Synthesis Detection by Isoelectrofocusing
CategoryDiagnostic Test
Description

Gold standard assay using HYDRAGEL CSF ISOFOCUSING kit on HYDRASYS 2 for qualitative detection of IgG oligoclonal banding in CSF and serum for multiple sclerosis diagnosis, with 100-fold increased sensitivity versus standard immunofixation. For neurology and multiple sclerosis testing laboratories.

15Connective Tissue Diseases Test Panel
CategoryDiagnostic Test Panel
Description

Comprehensive panel including ANA HEp-2 IFA, ANADetect, ANAscreen, anti-dsDNA, anti-histone, anti-nucleosome, anti-Jo-1, anti-Scl-70, anti-SS-A, anti-SS-B, anti-RNP/Sm, and anti-centromere B tests for CTD diagnosis including SLE, Sjogren's, and systemic sclerosis. For autoimmune disease testing laboratories.

16Antiphospholipid Syndrome Test Panel
CategoryDiagnostic Test Panel
Description

Largest portfolio of ELISA-based tests for APS diagnostics including anti-cardiolipin, anti-beta-2-glycoprotein I, anti-prothrombin, anti-phosphatidyl serine, anti-phosphatidyl inositol, anti-phosphatidic acid, and anti-annexin V antibodies. For autoimmune disease testing laboratories.

17Vasculitis Test Panel
18Sebia Academy
CategoryService
Description

Educational service providing scientific and medical educational information including webinars, publications, and training resources for customers worldwide. For clinical laboratory professionals using Sebia products.

19Sebia Lean Service
CategoryService
Description

Modular and scalable laboratory optimization service designed to enhance laboratory performance with customized product and management solutions. For clinical laboratories using Sebia products.

20Sebia Service
CategoryService
Description

Technical and scientific support service providing daily assistance for laboratory professionals using Sebia products. For clinical laboratory customers.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-20
Description

Exclusive global strategic partnership focused on developing new diagnostic tests for early detection and monitoring of sepsis. Combines Sebia's expertise in blood sample analysis with ABIONYX Pharma's lipid biology and clinical studies capabilities.

Strategic tierCoreTypeTechnology or Integration
Description

CAPILLARYS 3 TERA TLA connects to Inpeco FlexLab automation track enabling total lab automation integration for high-volume laboratories.

Strategic tierCoreTypeTechnology or Integration
Description

CAPILLARYS 3 TERA TLA connects to Siemens Healthineers Aptio automation track enabling total lab automation integration.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Sebia acquired ORGENTEC Diagnostika from Water Street Healthcare Partners in 2021, expanding capabilities in autoimmunity, infectious diseases, and clinical trials. ORGENTEC had previously acquired Arotec and Corgenix.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Sebia acquired ZEUS Scientific in 2022, a New Jersey-based IVD company specializing in autoimmune and infectious diseases including Lyme disease, expanding Sebia's presence in the U.S. market.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Long-established US specialty manufacturer of clinical electrophoresis and hemostasis instruments and reagents. Directly comparable to Sebia's CAPILLARYS and HYDRASYS platforms, especially in protein electrophoresis and hemoglobinopathy screening.

TypeBroad incumbent
Description

Major IVD incumbent whose Aptio automation track integrates with Sebia's CAPILLARYS 3 TERA TLA, while also competing in HbA1c, hemoglobin, and broader clinical chemistry. Significant overlap in hospital lab tenders.

TypeBroad incumbent
Description

Largest global IVD player with broad menus in HbA1c, clinical chemistry, and autoimmune serology. Competes with Sebia in diabetes monitoring and increasingly in specialty protein diagnostics through its cobas platform.

TypeBroad incumbent
Description

Diversified life science and clinical diagnostics company with a clinical electrophoresis product line (VARIANT, D-10) overlapping Sebia's hemoglobin and HbA1c testing. Larger portfolio and broader geographic reach make it a broad incumbent rather than direct niche competitor.

TypeDirect peer
Description

Specialty diagnostics division offering HPLC-based HbA1c analyzers (G8, G11) and immunoassay systems that directly compete with Sebia's HbA1c electrophoresis and Alegria 2 ELISA offerings.

6The Binding Site (Thermo Fisher Scientific)
TypeDirect peer
Description

Specialty immunology diagnostics company (acquired by Thermo Fisher) historically strongest in Freelite free light chain assays for multiple myeloma—directly competitive with Sebia's FLC Kappa & Lambda offering for plasma cell disorders.

7Beckman Coulter (Danaher)
TypeBroad incumbent
Description

Major IVD platform player with broad clinical chemistry, immunoassay, and hematology offerings that overlap with Sebia's HbA1c and hemoglobin testing, plus autoimmune serology menus.

8Abbott Diagnostics
TypeBroad incumbent
Description

Global IVD incumbent with overlapping HbA1c and clinical chemistry offerings on the ARCHITECT/Alinity platforms. Competes in hospital lab menus where Sebia's electrophoresis reagents are also positioned.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sebia

In Vitro Diagnostics (Clinical Laboratory Equipment and Reagents)sebia.com

Sebia is a global In Vitro Diagnostic company specializing in clinical protein electrophoresis instruments, reagents, and autoimmune disease tests, serving clinical diagnostic laboratories across 120+ countries with 20,000+ installed instruments and a recurring reagent revenue model.

What Sebia does

Sebia is a global In Vitro Diagnostic (IVD) company founded in 1967 and headquartered in Evry, France, specializing in clinical protein electrophoresis equipment and reagents. The company provides a comprehensive portfolio of instruments, tests, software, and services to clinical diagnostic laboratories across 120+ countries, with 20,000+ installed instruments and 1,300+ employees worldwide. Its core technology platforms include Capillary Electrophoresis (CAPILLARYS 3 family, MINICAP), Gel Electrophoresis (HYDRASYS 2), IFA automation (dIFine microscope with AI-powered pattern recognition), and random-access ELISA (Alegria 2 with 130+ tests). The proprietary PHORESIS software manages data analysis across electrophoresis instruments, while Sebia Academy, Sebia Lean Service, and Sebia Service provide education, optimization, and technical support.

The company's test menu addresses five primary clinical areas: oncology (Multiple Myeloma diagnosis via serum protein electrophoresis, immunofixation, immunotyping, and Free Light Chains with 96.8% concordance to IMWG criteria), metabolic disorders (HbA1c for diabetes, CDT for alcoholism), hemoglobinopathies (newborn and patient screening covering 500+ variants), autoimmune diseases (ANA, ANCA, vasculitis, connective tissue disease panels), and infectious diseases. Sebia holds regulatory clearances including FDA approvals for FLC Kappa & Lambda assays (2024) and CAPILLARYS 3 DBS (2024), plus IFCC standardization for CDT testing.

Sebia's business model combines hardware sales (instruments) with high-margin recurring revenue from proprietary test reagents and consumables tied to the installed instrument base, supplemented by service and education revenue. The company distributes through a global direct enterprise sales force targeting clinical laboratories, with integration partnerships with major lab automation vendors (Inpeco FlexLab, Siemens Healthineers Aptio, PerkinElmer). The company is privately held, with private equity firms CVC Funds, La Caisse, and Téthys Invest as existing investors; in late 2025, Warburg Pincus announced acquisition of a significant minority stake (EC-approved December 2025, closing expected Q1 2026). Sebia has pursued an active M&A strategy, acquiring Orgentec Diagnostika (2021) and ZEUS Scientific (2022) to expand autoimmune and infectious disease capabilities, and entered a strategic partnership with ABIONYX Pharma (2025) for sepsis diagnostics development.

Sebia firmographics

Firmographics
Name
Sebia
Legal name
Sebia S.A.
Website
https://sebia.com
Company type
Private
Founded year
1967
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Sebia is a global In Vitro Diagnostic company specializing in clinical protein electrophoresis instruments, reagents, and autoimmune disease tests, serving clinical diagnostic laboratories across 120+ countries with 20,000+ installed instruments and a recurring reagent revenue model.
Ownership category
akta.pro rank

Sebia industry classification

Industry
Product category
In Vitro Diagnostics (Clinical Laboratory Equipment and Reagents)
NAICS
Analytical Laboratory Instrument Manufacturing (334516), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAHAAAB
Hematology & Coagulation Diagnostics
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAHAAAM
IVD Reagents, Assay Kits & Consumables (Non-instrument)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics

Keywords

  • In vitro diagnostics
  • Capillary electrophoresis
  • Protein electrophoresis
  • Diagnostic reagents
  • Clinical laboratory equipment

Where Sebia is headquartered

Location

Headquarters

HQ city
Lisses
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Sebia business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. IVD Instruments and Hardware: Sale of electrophoresis instruments including CAPILLARYS family, MINICAP, HYDRASYS, dIFine, and Alegria 2 systems to clinical laboratories.
  2. Diagnostic Reagents and Tests: Recurring revenue from proprietary test reagents, consumables, and assay kits for the installed instrument base covering protein electrophoresis, immunotyping, FLC, HbA1c, hemoglobin, CDT, autoimmune and infectious disease tests.
  3. Service and Support: Sebia Service for technical and scientific support, Sebia Lean Service for laboratory performance optimization, and Sebia Academy for customer education.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Sebia product offering

Product offering

Core offering

Sebia manufactures and sells in vitro diagnostic instruments (capillary electrophoresis, gel electrophoresis, IFA automation, and random-access ELISA systems), proprietary test reagents and consumables, the PHORESIS data analysis software, and laboratory support services for clinical diagnostic laboratories worldwide. Its test portfolio spans multiple myeloma, diabetes, hemoglobinopathies, autoimmune, and infectious disease diagnostics, with 20,000+ instruments installed in 120+ countries.

Product overview

Sebia is a global specialized In Vitro Diagnostic company providing a comprehensive portfolio of instruments, tests, software, and services for clinical diagnosis laboratories. The core technology platform includes Capillary Electrophoresis instruments (CAPILLARYS 3 family, MINICAP), Gel Electrophoresis (HYDRASYS 2), IFA automation (dIFine microscope and P30 processor), and random-access ELISA (Alegria 2). These instruments run tests across key clinical areas: Oncology (Multiple Myeloma diagnosis via serum protein electrophoresis, immunofixation, immunotyping, and Free Light Chains), Metabolic Disorders (HbA1c for diabetes, CDT for alcoholism), Hemoglobinopathies (newborn and patient screening), and Autoimmune/Infectious Diseases (ANA, ANCA, anti-CCP, anti-MCV, thyroid, celiac, vasculitis panels). The proprietary PHORESIS software manages data analysis across electrophoresis instruments, while Sebia Academy, Sebia Lean Service, and Sebia Service provide education and support. Acquired brands include Orgentec (autoimmune/infectious disease ELISAs) and Zeus Scientific. The MySebia portal provides customer self-service access.

Differentiator

Problem solved

Functional benefit

Brands

  • Orgentec: Brand under Sebia offering for autoimmune and infectious disease diagnostic tests, including ORG-prefixed products.
  • dIFine
  • Alegria 2
  • CAPILLARYS
  • HYDRASYS

Products and services

  • CAPILLARYS 3 TERA TLA High-throughput capillary electrophoresis instrument with total lab automation connectivity to Inpeco FlexLab and Siemens Healthineers Aptio tracks, processing up to 87 protein electrophoresis results per hour. For high-volume clinical diagnostic laboratories.
  • CAPILLARYS 3 TERA Multiparametric capillary electrophoresis instrument combining precision, high-quality separation, and high throughput for protein electrophoresis, immunotyping, and HbA1c testing. For medium-to-high volume clinical laboratories.
  • CAPILLARYS 3 OCTA Capillary electrophoresis system for medium-to-high volume laboratories requiring multiple simultaneous electrophoretic separations.
  • CAPILLARYS 3 DBS FDA-cleared automated capillary electrophoresis instrument dedicated to newborn hemoglobin disorders screening using dried blood spots, with up to 70 samples/hour throughput and full traceability from sample punch to result. For newborn screening programs.
  • MINICAP FLEX-PIERCING Compact, fully automated capillary electrophoresis instrument for small-to-medium size laboratories offering seven available techniques including protein, immunotyping, HbA1c, hemoglobin, and CDT testing.
  • dIFine automated microscope Fully automated IFA microscope with AI-powered ANA pattern recognition using computer vision, processing up to 96 fields per run at 8 seconds per well, with integrated image atlas for ICAP-compliant pattern validation. For autoimmune disease testing laboratories.
  • dIFine P30 processor Walk-away benchtop instrument for automated IFA slide processing, handling up to 240 samples and 30 slides per run with full traceability from dilution to cover slipping. For autoimmune and immunology laboratories.
  • HYDRASYS 2 SCAN FOCUSING Semi-automated gel electrophoresis instrument for isoelectrofocusing and immunofixation, used with HYDRAGEL kits for CNS IgG oligoclonal band detection in multiple sclerosis diagnosis. For clinical laboratories performing neurological disease testing.
  • Alegria 2 Fully automated random-access ELISA-based analyzer using Monotest technology for autoimmune and infectious disease diagnostics, offering a customizable panel of over 130 tests with continuous loading and on-board quality control. For clinical autoimmune and infectious disease laboratories.
  • PHORESIS Software Proprietary data analysis and interpretation software for Sebia electrophoresis assays, facilitating efficient result management and analysis across all Sebia instruments. For clinical laboratories running Sebia instruments.
  • Free Light Chains (FLC) Kappa & Lambda FDA-cleared ELISA assay for quantification of kappa and lambda free light chains in serum, used as an aid in diagnosis and monitoring of Multiple Myeloma and AL amyloidosis with 96.8% concordance to IMWG criteria. For clinical laboratories and oncology departments.
  • Carbohydrate Deficient Transferrin (CDT) IFCC-standardized biomarker test for chronic alcohol abuse detection using capillary electrophoresis, with CDTIFCC percent value automatically calculated. For clinical and forensic laboratories.
  • Hemoglobin Disorders Screening Capillary electrophoresis-based hemoglobin variant screening enabling high-resolution separation of Hb S, C, D, and E variants with accurate quantification of Hb A2 and Hb F, covering over 500 hemoglobin variants. For newborn screening and hemoglobinopathy reference laboratories.
  • CNS Local IgG Synthesis Detection by Isoelectrofocusing Gold standard assay using HYDRAGEL CSF ISOFOCUSING kit on HYDRASYS 2 for qualitative detection of IgG oligoclonal banding in CSF and serum for multiple sclerosis diagnosis, with 100-fold increased sensitivity versus standard immunofixation. For neurology and multiple sclerosis testing laboratories.
  • Connective Tissue Diseases Test Panel Comprehensive panel including ANA HEp-2 IFA, ANADetect, ANAscreen, anti-dsDNA, anti-histone, anti-nucleosome, anti-Jo-1, anti-Scl-70, anti-SS-A, anti-SS-B, anti-RNP/Sm, and anti-centromere B tests for CTD diagnosis including SLE, Sjogren's, and systemic sclerosis. For autoimmune disease testing laboratories.
  • Antiphospholipid Syndrome Test Panel Largest portfolio of ELISA-based tests for APS diagnostics including anti-cardiolipin, anti-beta-2-glycoprotein I, anti-prothrombin, anti-phosphatidyl serine, anti-phosphatidyl inositol, anti-phosphatidic acid, and anti-annexin V antibodies. For autoimmune disease testing laboratories.
  • Vasculitis Test Panel
  • Sebia Academy Educational service providing scientific and medical educational information including webinars, publications, and training resources for customers worldwide. For clinical laboratory professionals using Sebia products.
  • Sebia Lean Service Modular and scalable laboratory optimization service designed to enhance laboratory performance with customized product and management solutions. For clinical laboratories using Sebia products.
  • Sebia Service Technical and scientific support service providing daily assistance for laboratory professionals using Sebia products. For clinical laboratory customers.

Quantifiable outcome

  • Clinical performance of 96.8% concordance for FLC testing based on IMWG criteria
  • +2 more outcomes

Companies that use Sebia

Customer profile

Named customers8 records

Segments6 records

Ideal customer profiles3 records

Sebia technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability2 records

Feature6 records

Sebia partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • ABIONYX PharmacoreStrategic or Co-development Partner · 20 November 2025Exclusive global strategic partnership focused on developing new diagnostic tests for early detection and monitoring of sepsis. Combines Sebia's expertise in blood sample analysis with ABIONYX Pharma's lipid biology and clinical studies capabilities.
  • Inpeco FlexLabcoreTechnology or IntegrationCAPILLARYS 3 TERA TLA connects to Inpeco FlexLab automation track enabling total lab automation integration for high-volume laboratories.
  • Siemens Healthineers AptiocoreTechnology or IntegrationCAPILLARYS 3 TERA TLA connects to Siemens Healthineers Aptio automation track enabling total lab automation integration.
  • ORGENTEC DiagnostikacoreStrategic or Co-development PartnerSebia acquired ORGENTEC Diagnostika from Water Street Healthcare Partners in 2021, expanding capabilities in autoimmunity, infectious diseases, and clinical trials. ORGENTEC had previously acquired Arotec and Corgenix.
  • ZEUS ScientificcoreStrategic or Co-development PartnerSebia acquired ZEUS Scientific in 2022, a New Jersey-based IVD company specializing in autoimmune and infectious diseases including Lyme disease, expanding Sebia's presence in the U.S. market.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Sebia competitors and assessment

Company assessment

Direct peers

  • Helena Laboratories: Long-established US specialty manufacturer of clinical electrophoresis and hemostasis instruments and reagents. Directly comparable to Sebia's CAPILLARYS and HYDRASYS platforms, especially in protein electrophoresis and hemoglobinopathy screening.
  • Tosoh Bioscience: Specialty diagnostics division offering HPLC-based HbA1c analyzers (G8, G11) and immunoassay systems that directly compete with Sebia's HbA1c electrophoresis and Alegria 2 ELISA offerings.
  • The Binding Site (Thermo Fisher Scientific): Specialty immunology diagnostics company (acquired by Thermo Fisher) historically strongest in Freelite free light chain assays for multiple myeloma—directly competitive with Sebia's FLC Kappa & Lambda offering for plasma cell disorders.

Broad incumbents

  • Siemens Healthineers: Major IVD incumbent whose Aptio automation track integrates with Sebia's CAPILLARYS 3 TERA TLA, while also competing in HbA1c, hemoglobin, and broader clinical chemistry. Significant overlap in hospital lab tenders.
  • Roche Diagnostics: Largest global IVD player with broad menus in HbA1c, clinical chemistry, and autoimmune serology. Competes with Sebia in diabetes monitoring and increasingly in specialty protein diagnostics through its cobas platform.
  • Bio-Rad Laboratories: Diversified life science and clinical diagnostics company with a clinical electrophoresis product line (VARIANT, D-10) overlapping Sebia's hemoglobin and HbA1c testing. Larger portfolio and broader geographic reach make it a broad incumbent rather than direct niche competitor.
  • Beckman Coulter (Danaher): Major IVD platform player with broad clinical chemistry, immunoassay, and hematology offerings that overlap with Sebia's HbA1c and hemoglobin testing, plus autoimmune serology menus.
  • Abbott Diagnostics: Global IVD incumbent with overlapping HbA1c and clinical chemistry offerings on the ARCHITECT/Alinity platforms. Competes in hospital lab menus where Sebia's electrophoresis reagents are also positioned.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Sebia social profiles

Digital presence

Sebia financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sebia leadership team

Management profile

Number of profiles

Profiles3 records

Sebia subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Sebia funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sebia M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sebia

What does Sebia do?

Sebia manufactures and sells in vitro diagnostic instruments (capillary electrophoresis, gel electrophoresis, IFA automation, and random-access ELISA systems), proprietary test reagents and consumables, the PHORESIS data analysis software, and laboratory support services for clinical diagnostic laboratories worldwide. Its test portfolio spans multiple myeloma, diabetes, hemoglobinopathies, autoimmune, and infectious disease diagnostics, with 20,000+ instruments installed in 120+ countries.

Is Sebia a public or private company?

Sebia is a private company. It is classified as private equity controlled and is currently operating.

When was Sebia founded?

Sebia was founded in 1967. It employs 1,001 to 5,000 people.

Where is Sebia based?

Sebia is headquartered in Lisses, France, in the Europe region.

How does Sebia make money?

Three revenue lines are on record. IVD Instruments and Hardware is the primary driver. The others are diagnostic Reagents and Tests and service and Support.

Who are Sebia's main competitors?

Direct peers on record are Helena Laboratories, Tosoh Bioscience and The Binding Site (Thermo Fisher Scientific). Broad incumbents are Siemens Healthineers, Roche Diagnostics, Bio-Rad Laboratories, Beckman Coulter (Danaher) and Abbott Diagnostics.

Does Sebia have an API?

No public API is recorded for Sebia.

What industry is Sebia in?

Sebia's product category is In Vitro Diagnostics (Clinical Laboratory Equipment and Reagents). Its primary akta.pro industry code is HLAHAAAB, Hematology & Coagulation Diagnostics, with a secondary code of HLAHAAAM, IVD Reagents, Assay Kits & Consumables (Non-instrument). Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Medical BuyerSebia appoints Nitin Kapoor as product marketing managerSebia has appointed Nitin Kapoor as product marketing manager for autoimmune and infectious diseases. Kapoor brings over 12 years of marketing experience, having previously served as deputy marketing manager at BD and marketing services manager at Promega. He holds an MBA from Amity University.Business Wire BlogABIONYX Pharma and SEBIA Announce an Exclusive Global Strategic Partnership to Transform Sepsis DiagnosisABIONYX Pharma and SEBIA announced an exclusive global strategic partnership to develop new diagnostic tests for the early detection and dynamic monitoring of sepsis treatment. The partnership combines SEBIA's expertise in preparative analytical chemistry for blood samples with ABIONYX Pharma's expertise in lipid biology and sepsis clinical studies, overseen by a Joint Steering Committee. The global sepsis diagnostics market is estimated to exceed $1.5 billion by 2030 with approximately 9% annual growth, as the two companies aim to address a condition that affects over 50 million people annually and kills more than 11 million worldwide.ThemiddlemarketWarburg Pincus to Acquire Minority Stake in SebiaWarburg Pincus has agreed to acquire a significant minority stake in Sebia, a global diagnostics company, in a transaction expected to close by Q1 2026. Existing investors including CVC Funds, La Caisse, and Téthys Invest will retain meaningful ownership while Sebia continues independent operations from France. The deal remains subject to employee consultations and customary regulatory approvals.Warburg PincusSebia and Warburg Pincus Partner to Drive Innovation in DiagnosticsWarburg Pincus has entered exclusive negotiations to acquire a significant minority stake in Sebia, a global leader in specialty diagnostics. Existing shareholders CVC Funds, La Caisse, and Téthys Invest will remain invested as the company continues its independent operations from France. The transaction is subject to regulatory approvals and employee consultations, with closing expected no earlier than Q1 2026.BloombergWarburg Pincus Nears Deal for Stake in France’s SebiaWarburg Pincus is nearing a deal to acquire a stake in French diagnostics provider Sebia, with talks advanced. The firm could buy a more than 30% stake, potentially valuing Sebia at around €5.5 billion ($6.4 billion). An agreement could be reached in the coming days.BloombergCVC Explores Options for Stake in Diagnostics Firm SebiaCVC Capital Partners is evaluating options for its majority stake in French diagnostics firm Sebia. The stake could be valued at about €6 billion ($6.5 billion) in a deal, though the valuation may change as deliberations continue. CVC may decide to keep the asset for longer.ZeusscientificNews & EventsSebia has announced the acquisition of ZEUS Scientific, an in vitro diagnostic company based in New Jersey, on October 11, 2022. This acquisition aims to enhance Sebia's product portfolio and capabilities in the autoimmune diagnostics sector. It reinforces Sebia's operations in the United States, the largest market for in vitro diagnostics, and establishes a collaboration that is expected to drive innovation and global growth.PharmiWeb.comSebia acquires Zeus ScientificSebia announced the acquisition of Zeus Scientific, an In Vitro Diagnostic company based in New Jersey, to expand its capabilities and product portfolio in autoimmunity diagnostics. The strategic move reinforces Sebia's operations in the United States, the largest IVD market, although specific financial terms were not disclosed.GlobeNewswireSerum Free Light Chain Assays Market Size [2022-2029] | Industry Trends, Share, Growth, SWOT Analysis, Market Drivers, Restraints, Opportunities, And Key Developments with Global ForecastThe global serum free light chain assays market is expected to grow substantially during the forecast period, driven by rising cases of plasma cell disorders and multiple myeloma. Multiple myeloma cases have surged to 4.4% per 100,000 globally, and new-generation assays from Sebia and FLC Kappa are enhancing treatment efficiency.PR NewswireSebia and Metafora biosystems form Strategic partnership to Develop Advanced In Vitro Diagnostics testsSebia and Metafora biosystems announced a strategic partnership to develop in-vitro diagnostics, with Sebia acquiring a minority stake in Metafora. The partnership focuses on hematology and oncology, targeting multiple myeloma and metabolic diseases. Metafora plans to launch its first diagnostic test in Europe in 2022.